Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms.
Journal: Biological psychiatry global open science
Published: December 21, 2020
Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.
Journal: Clinical pharmacokinetics
Published: June 14, 2020
Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: May 04, 2020
A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia.
Journal: Journal of clinical psychopharmacology
Published: June 18, 2019
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.
Journal: Molecular psychiatry
Published: August 17, 2016
AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study.
Journal: Schizophrenia research
Published: October 28, 2015
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.
Journal: Molecular psychiatry
Published: June 02, 2015
Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.
Journal: Journal of clinical psychopharmacology
Published: October 14, 2014
Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia.
Journal: Biomarkers in medicine
Published: December 12, 2013
The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.
Journal: British journal of clinical pharmacology
Published: December 05, 2012
Open-label, randomized, parallel-group controlled clinical trial of massage for treatment of depression in HIV-infected subjects.
Journal: Journal of alternative and complementary medicine (New York, N.Y.)
Published: October 27, 2012
Last Updated: 09/26/2026